Vitamin D receptor has antiproliferative effects in pulmonary arterial hypertension, but receptor expression is downregulated ...

California’s XOMA Royalty Corporation has announced that it now owns an economic interest in seralutinib, a Phase III asset being studied in pulmonary arterial hypertension (PAH), through its $20 ...

Under the commercialisation agreement with Getz Healthcare, Beyond Air is set to obtain a $1m milestone payment.

Takeda Pharmaceutical Company Limited (NYSE:TAK) entered into an exclusive licensing agreement with Keros Therapeutics, Inc. ...

Presentations at the 2024 Asembia Specialty Pharmacy Summit focused on reshaping specialty pharmacy while keeping patients ...

The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Penn Highlands Healthcare welcomes certified family nurse practitioner Eryn Thomas, FNP-C, to its medical staff.

Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a ...

As men age, the likelihood of erectile dysfunction (ED) becomes more common. At age 40, around about 4 in 10 men may struggle ...

Having a spouse with a Type D ("distressed") personality was associated with adverse cardiovascular outcomes for patients ...

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of ...